tetano
Editor, Senior Moderator
J Med Virol. 2020 May 14. doi: 10.1002/jmv.26003. [Epub ahead of print]
Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity.
Huang J[SUP]1[/SUP], Cheng A[SUP]2[/SUP], Kumar R[SUP]3[/SUP], Fang Y[SUP]4[/SUP], Chen G[SUP]5[/SUP], Zhu Y[SUP]1[/SUP], Lin S[SUP]1[/SUP].
Author information
Abstract
BACKGROUND:
The coronavirus disease 2019 (COVID-19) has evolved into a pandemic rapidly. Most of the literature showed that the elevated liver enzymes in COVID-19 are of little clinical significance. Lower albumin level is seen in severe COVID-19 and is not parallel to the changes in ALT and AST levels. We aimed to explore the impact of hypoalbuminemia in COVID-19.
METHODS:
This retrospective cohort study included adult patients with confirmed COVID-19. The relationship between hypoalbuminemia and death was studied using binary logistic analysis.
RESULTS:
A total of 299 adult patients were included, 160 (53.5%) were males and the average age was 53.4 ? 16.7 years. The median time from the onset of illness to admission was 3 days (interquartile ranges 2-5). Approximately one-third of patients had comorbidities. Hypoalbuminemia (<35g/L) was found in 106 (35.5%) patients. The difference in albumin was considerable between survivors and non-survivors (37.6 ? 6.2 vs. 30.5 ? 4.0, P < 0.001). Serum albumin level was inversely correlated to white blood cell (r = -0.149, P = 0.01) and neutrophil to lymphocyte ratio (r = -0.298, P <0.001). Multivariate analysis showed the presence of comorbidities (OR = 6.816, 95%CI: 1.361-34.133), lymphopenia (OR = 13.130, 95%CI: 1.632-105.658) and hypoalbuminemia (OR = 6.394, 95%CI: 1.315-31.092) were independent predictive factors for mortality.
CONCLUSIONS:
Hypoalbuminemia was associated with the outcome of COVID-19. The potential therapeutic value of albumin infusion in COVID-19 should be further explored at the earliest. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
KEYWORDS:
COVID-19; hypoalbuminemia; mortality; prediction; risk factor
PMID:32406952DOI:10.1002/jmv.26003
Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity.
Huang J[SUP]1[/SUP], Cheng A[SUP]2[/SUP], Kumar R[SUP]3[/SUP], Fang Y[SUP]4[/SUP], Chen G[SUP]5[/SUP], Zhu Y[SUP]1[/SUP], Lin S[SUP]1[/SUP].
Author information
Abstract
BACKGROUND:
The coronavirus disease 2019 (COVID-19) has evolved into a pandemic rapidly. Most of the literature showed that the elevated liver enzymes in COVID-19 are of little clinical significance. Lower albumin level is seen in severe COVID-19 and is not parallel to the changes in ALT and AST levels. We aimed to explore the impact of hypoalbuminemia in COVID-19.
METHODS:
This retrospective cohort study included adult patients with confirmed COVID-19. The relationship between hypoalbuminemia and death was studied using binary logistic analysis.
RESULTS:
A total of 299 adult patients were included, 160 (53.5%) were males and the average age was 53.4 ? 16.7 years. The median time from the onset of illness to admission was 3 days (interquartile ranges 2-5). Approximately one-third of patients had comorbidities. Hypoalbuminemia (<35g/L) was found in 106 (35.5%) patients. The difference in albumin was considerable between survivors and non-survivors (37.6 ? 6.2 vs. 30.5 ? 4.0, P < 0.001). Serum albumin level was inversely correlated to white blood cell (r = -0.149, P = 0.01) and neutrophil to lymphocyte ratio (r = -0.298, P <0.001). Multivariate analysis showed the presence of comorbidities (OR = 6.816, 95%CI: 1.361-34.133), lymphopenia (OR = 13.130, 95%CI: 1.632-105.658) and hypoalbuminemia (OR = 6.394, 95%CI: 1.315-31.092) were independent predictive factors for mortality.
CONCLUSIONS:
Hypoalbuminemia was associated with the outcome of COVID-19. The potential therapeutic value of albumin infusion in COVID-19 should be further explored at the earliest. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
KEYWORDS:
COVID-19; hypoalbuminemia; mortality; prediction; risk factor
PMID:32406952DOI:10.1002/jmv.26003